GENE — Genetic Technologies Share Price
Last trade - 00:00- $5.95m
- $5.86m
- AU$7.66m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.23 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -600.03% | ||
| Return on Equity | -184.98% | ||
| Operating Margin | -155.86% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.01 | 0.12 | 6.79 | 8.69 | 7.66 | n/a | n/a | 213.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its EasyDNA brand. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company's segments include EasyDNA and AffinityDNA. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses.
Directors
- Peter Rubenstein CHM
- Simon Morriss CEO
- Michael Tonroe CFO
- Mark Ostrowski CEX (50)
- Stan Sack COO
- Jerzy Muchnicki EDR
- Richard Allman OTH (55)
- M. Luisa Ashdown OTH (57)
- Susan Gross OTH
- Diana Newport OTH (57)
- Nick Burrows NED
- Lindsay Wakefield NID
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- January 5th, 1987
- Public Since
- July 30th, 1987
- No. of Shareholders
- 4,528
- No. of Employees
- 58
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 245,362,077
- Address
- Suite 7, Level 1, 321 Chapel Street, MELBOURNE, 3181
- Web
- https://www.gtglabs.com/
- Phone
- +61 394151135
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for GENE
Similar to GENE
23andMe Holding Co.
NASDAQ Capital Market
ADVANCED BIOMED
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
Avalon Globocare
NASDAQ Capital Market
FAQ
As of Today at 19:48 UTC, shares in Genetic Technologies are trading at $0.77. This share price information is delayed by 15 minutes.
Shares in Genetic Technologies last closed at $0.77 and the price had moved by -77.5% over the past 365 days. In terms of relative price strength the Genetic Technologies share price has underperformed the S&P500 Index by -82.03% over the past year.
There is no consensus recommendation for this security.
Find out moreGenetic Technologies does not currently pay a dividend.
Genetic Technologies does not currently pay a dividend.
Genetic Technologies does not currently pay a dividend.
To buy shares in Genetic Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.77, shares in Genetic Technologies had a market capitalisation of $5.95m.
Here are the trading details for Genetic Technologies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GENE
Based on an overall assessment of its quality, value and momentum Genetic Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genetic Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -69.76%.
As of the last closing price of $0.77, shares in Genetic Technologies were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genetic Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genetic Technologies' management team is headed by:
- Peter Rubenstein - CHM
- Simon Morriss - CEO
- Michael Tonroe - CFO
- Mark Ostrowski - CEX
- Stan Sack - COO
- Jerzy Muchnicki - EDR
- Richard Allman - OTH
- M. Luisa Ashdown - OTH
- Susan Gross - OTH
- Diana Newport - OTH
- Nick Burrows - NED
- Lindsay Wakefield - NID